Summary of Use during Lactation

Information in this record refers to the use of oxygen-15 radiopharmaceuticals as diagnostic agents. United States and international international authorities state that breastfeeding need not be interrupted after administration of radiopharmaceuticals containing oxygen-15.[1,2]

Drug Levels

Oxygen 15 decays by positron emission with a half-life of 2.04 minutes.[2]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Mattsson S, Johansson L, Leide Svegborn S, et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. ICRP Publication 128. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP. 2015;44(2) Suppl:319–21. PMID. [PubMed: 26069086]

2.

Dilsizian V, Metter D, Palestro C, et al. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material. Final report submitted: January 31, 2019. https://www​.nrc.gov/docs​/ML1903/ML19038A498.pdf.

Substance Name

Oxygen-15

CAS Registry Number

13982-43-9

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Oxygen Radioisotopes

Diagnostic Agents